A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT06234605 |
|
Recruitment Status :
Recruiting
First Posted : January 31, 2024
Last Update Posted : May 1, 2024
|
Sponsor:
HiberCell, Inc.
Collaborator:
Merck Sharp & Dohme LLC
Information provided by (Responsible Party):
HiberCell, Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | November 2026 |
| Estimated Study Completion Date : | November 2027 |